FINWIRES · TerminalLIVE
FINWIRES

Xuanzhu Biopharmaceutical Receives Chinese Regulatory Nod to Begin Trials of An Jiu Wei

-- Xuanzhu Biopharmaceutical (HKG:2575) said it received Chinese regulatory approval to begin phase 3 clinical trials of its drug An Jiu Wei to treat Helicobacter pylori, according to a Hong Kong bourse filing Wednesday.

The firm plans to enroll 556 adult subjects in the study.

An Jiu Wei is already approved in China as a treatment of duodenal ulcer.

相关文章